Testosterone Cypionate, Alcohol

Indications and usage: Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.

CLINICAL PHARMACOLOGY Endogenous androgens are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorus, and decreased urinary excretion of calcium.

With Approximately 6–15 hours terminal plasma half-life for Testosterone Cypionate, Alcohol residence kinetics and Estimated 57%–69% oral systemic absorption for Testosterone Cypionate, Alcohol bioavailability, Testosterone Cypionate, Alcohol undergoes phase i/ii hepatic conjugation of testosterone cypionate, alcohol coupled with glomerular and tubular renal excretion and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–3 hours post-dose for testosterone cypionate, alcohol.

Standard adult regimens span Kit, Organ-function-adjusted Testosterone Cypionate, Alcohol maintenance interval. Prescribers screen specifically against contraindications 1.; known hypersensitivity to the drug 2.; males with carcinoma of the breast 3., while community micro-logs most frequently note nausea (10.2% of reports), headache (7.4% of reports), dizziness (6.3% of reports).